anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a method and a device for acquiring lung cancer TNM by stages. The method comprises the following steps: a first target nodule in the first medical image is identified. And matching the first target nodule in the second medical image to obtain a second target nodule in the second medical image. And acquiring the long and short diameters of the second target nodule, and generating a T stage according to at least the long and short diameters of the second target nodule. An abnormal lymph node in the first medical image is identified, and an N stage is generated by determining whether the abnormal lymph node has metastasis. Identifying whether a first target nodule in the first medical image has a distant metastasis, and generating an M stage according to whether the first target nodule has the distant metastasis. And generating TNM stages according to the T stage, the N stage and the M stage. The first medical image and the second medical image are different modality medical images of the same patient and the same part. The scheme of the invention effectively improves the generation efficiency of TNM stages, is convenient for doctors to quickly know the illness state of patients and improves the diagnosis efficiency.
The investigators also propose a study to investigate the effects of communal drumming in reducing anxiety and increasing connectedness within drum circle community. Investigators hypothesize that these intervention will lead to reductions in scores on stress scales and will provide preliminary data for studies evaluating these types of community programs as an adjunct to the standard of care.

Individuals who attend periodic (i.e. weekly) drum circles will be recruited to join an 8-week paradigm. Drum circle sessions may audio recorded and participants will be informed of this during the consent process. Participants may be asked to undergo Electroencepholography, functional Near Infrared Spectroscopy, and/or other physiological measures before, during, and after the circles. Upon completion of the experiments, participants will be asked to take part in a focus group that will provide valuable feedback on their experience with the mindfulness intervention. Focus groups will last 30-minutes to 1 hour and will occur in-person.
Immunogenic conjugate molecules comprising at least a portion of a capsular polysaccharide of a Streptococcus strain linked to at least a portion of an outer membrane protein of a Haemophilus strain are provided in which the immunogenicity of the capsular polysaccharide is increased. Particularly capsular polysaccharide from Streptococcus pneumoniae are linked to an outer membrane protein of a Haemophilus influenzae strain, which protein may be the P1, P2 or particularly the P6 outer membrane protein. Conjugate molecules comprising the P6 protein linked to a capsular polysaccharide from an encapsulated pathogen other than Streptococcus also are described, in which the immunogenicity of the capsular polysaccharide is enhanced. Such conjugate molecules may be incorporated into immunogenic compositions for protecting a host against disease caused by the Streptococcus strain and preferably also the Haemophilus strain. The conjugate molecules and antibodies specific for the capsular polysaccharide or specific for the outer membrane protein may be employed in diagnostic procedures and kits. A process for individually isolating P1, P2 and P6 outer membrane proteins from a Haemophilus strain also is provided.
The present invention provides a pharmaceutical composition for preventing or treating allergic or autoimmune diseases, which contains immunoglobulin, as an active ingredient, isolated from the blood of a patient who is suffering from an allergic or autoimmune disease. In addition, the disclosed invention provides another pharmaceutical composition for preventing or treating allergic or autoimmune diseases, which contains immunoglobulin isolated from the blood of another patient who is suffering from an allergic or autoimmune disease as an active ingredient. The present invention also provides a manufacturing method and a medicinal and pharmaceutical use of the composition of a medicine for preventing or treating allergic or autoimmune diseases. Also, the disclosed invention provides a method for preventing and treating allergic or autoimmune diseases, which includes administering the pharmaceutical composition to mammals. By administering the disclosed pharmaceutical composition to mammals, allergic or autoimmune diseases, which are hard to control with a current standard drug treatment method, can be treated. Therefore, through the pharmaceutical composition, the use thereof for preventing or treating allergic or autoimmune disease, and the prevention and treatment method using the same, allergic or autoimmune diseases whose symptoms are not easily treated with current standard drug treatment methods can be more effectively treated.
In the study group (20 patients) the CytoSorb filter will be installed in the CPB in a parallel circuit. An additional roller pump will drive the blood through the filter with a constant flow of 400 ml/min (max flow).
Two separate studies, idential in design, were planned and initiated under 2 protocol IDs and NCTs, i.e. study ACP-103-54 (NCT03999918) and ACP-103-059 (NCT03968159). In March 2020, recruitment of new patients was paused due to the emerging coronavirus disease 2019 (COVID-19) pandemic. At that point in time, about half of the planned patients had been randomized. The Sponsor decided to combine the 2 identically designed trials, with a prespecified combined statistical analysis plan. As a result, both trials were closed and proceeded with database lock and statistical analysis of the combined data. No further patients were enrolled.

This entry now includes the combined data of studies ACP-103-054 and ACP-103-059.
Subjects received at least 7 monthly intravitreal ranibizumab 0.5 mg injections and then never met the study-specific VA-OCT stability criteria from month 7 to month 14. Subjects were to receive 15 ranibizumab 0.5 mg injections.
Ulcerative colitis (UC) is a relapsing and reoccurring inflammatory bowel disease. The treatment effect of Alhagi maurorum and stem cell extracts on UC remains unclear. The aim of the present study was to investigate the protective role of Alhagi maurorum combined with stem cell extract on the intestinal mucosal barrier in an intestinal inflammation mouse model. Sixty mice were randomly divided into a control group, model group, Alhagi group, MSC group, and MSC/Alhagi group. MSC and Alhagi extract were found to reduce the disease activity index (DAI) scores in mice with colitis, alleviate weight loss, improve intestinal inflammation in mice (p < 0.05), preserve the integrity of the ileal wall and increase the number of goblet cells and mucin in colon tissues. Little inflammatory cell infiltration was observed in the Alhagi, MSC, or MSC/Alhagi groups, and the degree of inflammation was significantly alleviated compared with that in the model group. The distribution of PCNA and TNF-alpha in the colonic tissues of the model group was more disperse than that in the normal group (p < 0.05), and the fluorescence intensity was lower. After MSC/Alhagi intervention, PCNA and TNF-alpha were distributed along the cellular membrane in the MSC/Alhagi group (p < 0.05). Compared with that in the normal control group, the intensity was slightly reduced, but it was still stronger than that in the model group. In conclusion, MSC/Alhagi can alleviate inflammatory reactions in mouse colonic tissue, possibly by strengthening the protective effect of the intestinal mucosal barrier.
OBJECTIVE: Protein disulfide isomerase A3 (PDIA3) promotes the correct folding of newly synthesized glycoproteins in the endoplasmic reticulum. PDIA3 is overexpressed in most tumors, and it may become a biomarker of cancer prognosis and immunotherapy. Our study aims to detect the expression level of PDIA3 in gastric cancer (GC) and its association with GC development as wells as the underlying mechanisms.
METHODS: GC cell lines with PDIA3 knockdown by siRNA, CRISPR-cas9 sgRNAs or a pharmacological inhibitor of LOC14 were prepared and used. PDIA3 knockout GC cells were established by CRISPR-cas9-PDIA3 system. The proliferation, migration, invasion and cell cycle of GC cells were analyzed by cell counting kit-8 assay, wound healing assay, transwell assay and flow cytometry, respectively. Immunodeficient nude mice was used to evaluate the role of PDIA3 in tumor formation. Quantitative PCR and western blot were used for examining gene and protein expressions. RNA sequencing was performed to see the altered gene expression.
RESULTS: The expressions of PDIA3 in GC tissues and cells were increased significantly, and its expression was negatively correlated with the three-year survival rate of GC patients. Down-regulation of PDIA3 by siRNA, LOC14 or CRISPR-cas9 significantly inhibited proliferation, invasion and migration of GC cells TMK1 and AGS, with cell cycle arrested at G2/M phase. Meanwhile, decreased PDIA3 significantly inhibited growth of tumor xenograft in vivo. It was found that cyclin G1 (encoded by CCNG1 gene) expression was decreased by downregulation of PDIA3 in GC cells both in vitro and in vivo. In addition, protein levels of other cell cycle related factors including cyclin D1, CDK2, and CDK6 were also significantly decreased. Further study showed that STAT3 was associated with PDIA3-mediated cyclin G1 regulation.
CONCLUSION: PDIA3 plays an oncogenic role in GC. Our findings unfolded the functional role of PDIA3 in GC development and highlighted a novel target for cancer therapeutic strategy.
Sunitinib 37.5 mg daily. Lanreotide at the dose of 120 mg will be injected every 28 days as the reference treatment to control the carcinoid syndrome in both arms.
Gut microbiota is closely related to human gut neoplasm. According to recent statistics, the abundance of FN (Fusobacterium Nucleatum) is connected with the development and progression of CRCs (colorectal cancers). Subsequent research shows identifying multiple microbial-specific genes in human feces using qPCR (quantitative Polymerase Chain Reaction) may help diagnosis of early stage colorectal cancer. Currently little is known about the relationship between single abundance of specific gut microbiota and colorectal cancer in different stage. Moreover, finding early-stage CRCs is still of great challenge partially due to precancerous diseases like colorectal adenoma which remain difficult to differentiate from early-stage CRC under endoscope. Conventional clinic methods predicting CRCs largely depend on serum CEA (serum Carcino Embryonic Antigen) and OB(fecal occult blood test), which lack of adequate sensitivity and specificity especially in early stage CRCs. The investigators' work focuses on the abundance of gut microbiota in feces from people with colon neoplasm and its comparison with classical indicators such as CEA and OB, aiming to reveal and testify its potential role on assisting diagnosis of CRCs in different stage as a none-invasive cost-effective method.
The incidence of gastroesophageal reflux disease (GERD) is rising among Asian population. A recent systematic review showed among Chinese population, the prevalence of GERD can be up to 5% (2). Currently, the standard treatment for GERD is acid suppression using proton pump inhibitors (PPI) which can achieve a symptomatic relief of more than 90%. However, more than 50% of patients with GERD will required long term PPI. As the usual occurrence of GERD is at the age of 40 to 50, the need of long term PPI among these young adults renders them playing a sick role for a long period of time. This imposed a major impact on these patients' quality of life, and a significant medical expenditure to the society.

Since Rudolf Nissen first reported the use of fundoplication as a treatment of gastroesophageal reflux disease in 1956, there has been a development in variety of different fundoplication. It can be classified into a complete or partial wrapping at the lower esophageal sphincter around the esophago-gastric junction (EGJ). From the results of numerous randomized studies, Fundoplication is considered as an alternative to long term proton pump inhibitors. Recent controversies abound upon the use of partial or complete fundoplication. Several randomized studies reported that a partial fundoplication can reduce the incidence of post-operative dysphagia. However, this benefit is off-set by an increase in the incidence of recurrence. From our retrospective review on 28 patients treated by laparoscopic fundoplication, the recurrence of GERD is significantly higher in patients treated with partial compared to a complete fundoplication. The effectiveness of partial against complete Nissen fundoplication in control of reflux among Chinese patients is still unknown. Our study aimed to compare Laparoscopic Nissen fundoplication against Anterior partial on the control of gastroesophageal reflux disease.
The invention relates to a slider device (1) for determining an amount of insulin to be injected. Said slide device (1) consists of layered flat material sections forming a disk-shaped housing member (52) and comprises a plurality of slider tongues that can slide relative to one another. A first slider tongue (8) includes a plurality of input scales (16), each of which has an equidistant graduation, as well as a result scale (18) and can be manually gripped for proper usage and be slid in a first direction (14), a first parameter (37) being associated with each input scale (16). A second slider tongue (30) can slide in a second direction (32) running transversely to the first direction (14) and includes a window (34) which has a setting mark (35) and which can be placed in relation to the housing member (52) in such a way that each of the input scales (16) can be selectively viewed. A third slider tongue (38) can slide in the second direction (32) like the second slider tongue (30) and includes a plurality of windows (40) that are designed and arranged in such a way that when the third slider tongue (38) is in an appropriately selected sliding position relative to the housing member (52), the result scale (18) can be viewed. An edge of each window (40) of the third slider tongue (38) includes a reading value scale (42) having an equidistant graduation in the first direction, a second parameter (45) being associated with each reading value scale (42). The second slider tongue (30) and the third slider tongue (38) can be blocked in a specific position relative to the housing member (52), whereupon the first slider tongue (8) can be positioned relative to the setting mark (35) on the window (34) of the second slider tongue (30), and when a value appears on the reading value scale (42), a value corresponding to the amount of insulin to be injected can be read as a reading mark on the result scale (18).
FIELD: pharmacy. SUBSTANCE: composition has at least one ligand showing a selective activity to RXR s ,-receptors and at least one the second ligand showing a selective activity to RAR-α,-receptors in pharmaceutically acceptable carrier. Composition is used as a modulating agent for proliferation and/or differentiation of cells HL-60, in part, for systemic treatment of patients with acute promyelocytic leukemia. Composition can be used at low doses without tolerance and adverse effects. EFFECT: enhanced effectiveness of composition. 7 cl, 4 dwg, 2 ex
BACKGROUND: Intracranial atherosclerotic stenosis (ICAS) is one of the most important independent risk factors for stroke that is closely related to the occurrence of cognitive impairment. The relationship between ICAS and vascular cognitive impairment (VCI) remains unclear. Cerebral hemodynamic changes are one of the main causes of cognitive impairment. Computed tomographic perfusion (CTP) imaging can quantitatively analyze cerebral blood perfusion and quantify cerebral hemodynamic changes. Previous research on the relationship between hypoperfusion induced by ICAS and cognitive impairment, as well as its underlying mechanisms, remains relatively insufficient. This study is dedicated to elucidating the characteristics and potential mechanisms of cognitive impairment in ICAS patients with abnormal perfusion, utilizing CTP imaging as our primary investigative tool.
METHODS: This study recruited 82 patients who suffer from non-disabling ischemic stroke (IS group) and 28 healthy controls. All participants underwent comprehensive neuropsychological assessments both collectively and individually, in addition to CTP imaging. Within the patient group, we further categorized individuals into two subgroups: the ischemic penumbra group (IP, N = 28) and the benign oligemia group (BO, N = 54), based on CTP parameters-Tmax. The correlations between cognitive function and abnormal perfusion were explored.
RESULTS: The cognitive function, including the overall cognitive, memory, attention, executive functions, and language, was significantly impaired in the IS group compared with that in the control group. Further, there are statistical differences in the stroop color-word test-dot (Stroop-D) and Montreal Cognitive Assessment (MoCA) sub-items (memory + language) between the BO and IP groups. In the BO group, the score of Stroop-D is lower, and the MoCA sub-items are higher than the IP group. There is no correlation between CTP parameters and cognitive function.
CONCLUSION: Cognitive function is significantly impaired in patients with ICAS, which is related to cerebral perfusion. Executive, memory, and language function were better preserved in ICAS patients without IP. Hence, this study posits that managing hypoperfusion induced by ICAS may play a pivotal role in the development of VCI.
Patient received a sham tDCS (5sec of stimulation). The device runs during 20minutes and the anode was placed over the DLPF cortex. A behavioral assessment preceded and followed the stimulation.
PURPOSE:To keep a drug in liposome stably and to obtain a liposome preparation having long acting medicinal effects, by removing a solvent from a drug- containing W/O type emulsion to give liposome and dispersing the liposome into an aqueous solution having specific osmotic pressure. CONSTITUTION:A solvent (e.g. chloroform, alcohol, etc.) is removed from a drug (e.g. anti-inflammatory analgesic, anti-cancer drug, antibiotic, etc.)- containing W/O type emulsion by a conventional procedure to give REV liposome. Then the liposome is dispersed into an aqueous solution having at least >=20%, preferably >=50% higher osmotic pressure than a mounting solution does to give a liposome preparation. In the case of a liposome preparation to be administered into an organism, preferably the osmotic pressure of the dispersion is made approximately isotonic to that of an organism solution. The drug is stably retained in liposome and duration of medicinal effect and targeting effect on a specific organ are more readily developed.
PURPOSE:To obtain a coated preparation having high safety, by dispersing a solid drug into an acidic aqueous solution of a high polymer compound soluble in the stomach and adding an alkali to the dispersion. CONSTITUTION:A solid drug is dispersed into an acidic aqueous solution of a high polymer compound (e.g. polyvinyl acetal diethylamino-acetate) soluble in the stomach and an alkali (e.g. sodium hydroxide is added to a solid preparation. Since water is used as a medium, the preparation is safest and does not pollute environment. When the alkali is added to the dispersion to neutralize it finally, no acidic substance remains in a membrane and a coating film safe with time can be formed. The acidic aqueous solution used is adjusted to pH 1-5, preferably pH 2-4 by the use of citric acid, tartaric acid, etc. Existence of a surface active agent or a water-soluble high polymer plasticizer in the alkali addition can carry out coating with uniform particle size.
Participants will first receive a dose of S-268019-b via intramuscular (IM) injection on Day 1 and Day 29 during the initial vaccination period. After the initial vaccination period, participants will then receive a placebo IM injection (matching S-268019-b) on Day 225 and Day 253.
FIELD: biotechnology, microbiology. SUBSTANCE: invention relates to preparing the strain Vibrio cholerae KM 207 of classic biovar serovar Inaba as a producer of protective antigens (subunit B as component of choleraic toxin, the main colonizing factor of choleraic vibrio, toxin-coregulated adhesion pili, protective and immunogenic protein OmpU of external membrane). Method involves conjugative incorporation to cells the natural toxigenic strain Vibrio cholerae 569B of classic biovar serovar Inaba recombinant plasmid pCT105 (Km r Tc r ) with cloned genes of choleraic toxin and the following elimination of plasmid. The level of choleraic toxin production in the strain is increased by 2.6 times (23.4 mcg/ml), synthesis of toxin- -coregulated adhesion pili is elevated also and protein OmpU appeared. In culturing the strain addition of antibiotics to medium is not required as in the case of plasmid strains. Using the strain allows the enhancement of choleraic toxin production level, toxin-coregulated adhesion pili (this causes self-agglutination of cells in broth) and synthesizes protein OmpU of external membrane. Invention can be used for preparing vaccines and diagnostic test-systems. EFFECT: valuable properties of strain. 2 ex
INTRODUCTION: Although the maxillary nerve block (MNB) provides adequate pain relief in cleft palate surgery, it is not routinely used globally, and reported techniques are heterogeneous. This study aims to describe relevant anatomy and to present the preferred technique of MNB administration based on the current literature and the expert opinion of the authors.
METHOD AND MATERIALS: First, a survey was sent to 432 registrants of the International Cleft Palate Master Course Amsterdam 2023. Second, MEDLINE (PubMed interface) was searched for relevant literature on maxillary artery (MA) anatomy and MNB administration in pediatric patients.
RESULTS: Survey response rate was 18% (n=78). Thirty-five respondents (44.9%) used MNB for cleft palate surgery before the course. A suprazygomatic approach with needle reorientation towards the ipsilateral commissure before incision was most frequently reported, mostly without the use of ultrasound. Ten and 20 articles were included on, respectively, MA anatomy and MNB administration. A 47.5% to 69.4% of the MA's run superficial to the lateral pterygoid muscle and 32% to 52.5% medially. The most frequently described technique for MNB administration is the suprazygomatic approach. Reorientation of the needle towards the anterior aspect of the contralateral tragus appears optimal. Needle reorientation angles do not have to be adjusted for age, unlike needle depth. The preferred anesthetics are either ropivacaine or (levo)bupivacaine, with dexmedetomidine as an adjuvant.
CONCLUSION: Described MNB techniques are heterogeneous throughout the literature and among survey respondents and not routinely used. Further research is required comparing different techniques regarding efficacy and safety.